Novartis: EU panel backs new wet AMD treatment
(CercleFinance.com) - Novartis' treatment of wet age-related macular degeneration (AMD) has been recommended for approval by a European regulatory panel on Friday, bringing the drug another step closer to being marketed.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for investigational Beovu.
Wet AMD is caused by a protein that promotes abnormal blood vessel formation underneath the macula, the area of the retina responsible for sharp, central vision.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for investigational Beovu.
Wet AMD is caused by a protein that promotes abnormal blood vessel formation underneath the macula, the area of the retina responsible for sharp, central vision.
Copyright (c) 2019 CercleFinance.com. All rights reserved.